Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 6,830 Shares

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 6,830 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $71.31, for a total transaction of $487,047.30. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at approximately $16,681,120.44. This represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, June 3rd, William Lewis sold 5,472 shares of Insmed stock. The shares were sold at an average price of $71.50, for a total value of $391,248.00.
• On Tuesday, May 20th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $67.72, for a total value of $462,527.60.
• On Tuesday, May 20th, William Lewis sold 21,057 shares of Insmed stock. The shares were sold at an average price of $67.65, for a total transaction of $1,424,506.05.
• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $247,415.31.
• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The stock was sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $72.57, for a total transaction of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $70.16, for a total value of $479,192.80.
• On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50.

Insmed Stock Performance

INSM traded up $0.82 during midday trading on Friday, reaching $73.56. The company's stock had a trading volume of 704,483 shares, compared to its average volume of 2,071,480. Insmed Incorporated has a twelve month low of $55.74 and a twelve month high of $84.91. The company has a fifty day simple moving average of $69.25 and a 200 day simple moving average of $73.03. The stock has a market cap of $13.40 billion, a P/E ratio of -13.17 and a beta of 0.80. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.06) EPS. Research analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of INSM. Darwin Global Management Ltd. increased its holdings in Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after buying an additional 2,463,261 shares during the period. Norges Bank bought a new stake in Insmed in the fourth quarter valued at about $126,606,000. Adage Capital Partners GP L.L.C. raised its position in Insmed by 109.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after purchasing an additional 1,799,382 shares in the last quarter. Nuveen LLC bought a new position in Insmed during the first quarter worth about $88,351,000. Finally, Vanguard Group Inc. lifted its stake in Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Morgan Stanley boosted their price target on Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. Bank of America raised their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Guggenheim reiterated a "buy" rating and set a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and a consensus target price of $96.73.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.